Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936183 | PMC |
| http://dx.doi.org/10.3389/fphar.2023.1135803 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Periodic paralysis across the life course: age-related phenotype transition and sarcopenia overlap.
Front Neurol
December 2024
NextGen Precision Health, University of Missouri, Columbia, MO, United States.
In Periodic Paralysis (PP), a rare inherited condition caused by mutation in skeletal muscle ion channels, the phenotype changes with age, transitioning from the episodic attacks of weakness that give the condition its name, to a more degenerative phenotype of permanent progressive weakness and myopathy. This leads to disability and reduced quality of life. Neither the cause of this phenotype transition, nor why it occurs around the age of 40 is known.
View Article and Find Full Text PDFIntroduction: Anthropometric, demographic, genetic, and clinical features may affect cognitive, behavioral, and functional decline, while clinical trials seldom consider minimal clinically important differences (MCIDs) in their analyses.
Methods: MCIDs were reviewed taking into account features that may affect cognitive, behavioral, or functional decline in clinical trials of new disease-modifying therapies.
Results: The higher the number of comparisons of different confounders in statistical analyses, the lower values will be significant.
New strategies to manage the safety of cladribine in patients with multiple sclerosis.
Expert Opin Drug Saf
January 2025
Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy.
Brain organoid methodologies to explore mechanisms of disease in progressive multiple sclerosis.
Front Cell Neurosci
December 2024
Department of Clinical Neurosciences and NIHR Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom.
Multiple sclerosis (MS), a debilitating autoimmune disorder targeting the central nervous system (CNS), is marked by relentless demyelination and inflammation. Clinically, it presents in three distinct forms: relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS). While disease-modifying therapies (DMTs) offer some relief to people with RRMS, treatment options for progressive MS (pMS) remain frustratingly inadequate.
View Article and Find Full Text PDFTarget Therapy in Chronic Arthritis: The Unmet Needs, State-of-the-Art on Dual Biologic Treatments, and Future Perspectives.
J Clin Med
December 2024
Rheumatology Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria Policlinico Riuniti di Foggia, Università degli Studi di Foggia, 71121 Foggia, Italy.
Since the early 1990s, the introduction of biologic disease-modifying antirheumatic drugs (b-DMARDs) in managing rheumatological diseases has revolutionised the course of inflammatory chronic arthritis, improving the quality of life, slowing the radiographic progression, avoiding disability, preserving workability, and reducing mortality [...
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!